Clinical Efficacy and Economic Analysis of Three Ovulation Induction Drugs in IVF-ET/ICSI——A Retrospective Analysis Based on Real World

OBJECTIVE To compare the clinical efficacy of three ovulation-induction drugs on treatment outcomes in in vitro fertilization-embryo transfer/intracytoplasmic sperm injection(IVF-ET/ICSI) and economic analysis based on cost-minimization analysis and decision-making tree. METHODS A total of 282 cycles of IVF-ET/ICSI who received their treatment with controlled ovarian stimulation with antagonist regimen in the reproductive center of The International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University School of Medicine from March 2017 to December 2018 were retrospectively selected according to the different gonadotropin(Gn) drugs used by patients, and divided into group A:recombinant human follicle stimulating hormone α injection for 108 cycles; group B:urinary follicle stimulating hormone injection for 87 cycles; group C:recombinant human follicle stimulating hormone β injection for 87 cycles. The the general conditions, treatment costs, clinical efficacy of the three groups were observed, cost-minimization analysis were adopted to conduct pharmacoeconomic evaluation on the three therapeutic regimens. RESULTS There was no significant difference in general characteristics and treatment outcomes. The difference in total direct medical cost among the three groups was statistically significant(P<0.05). The total direct medical cost of group A, group B and group C were respectively 15 737.58 yuan, 14 782.68 yuan and 13 421.20 yuan. No obvious adverse drug reactions were found in three groups. The cost of group C was the smallest, the second was group B and the largest was group A. Therefore, treatment in group C is the most economical. CONCLUSION In the three regimens in treatment of IVF-ET/ICSI, recombinant follicle stimulating hormone β injection has more advantage in economic, followed by urinary follicle stimulating hormone for injection, while the recombinant follicle stimulating hormone injection has no advantage.